Clinical and genetic aspects of Turner’s syndrome by Ibarra Ramírez, Marisol & Martínez de Villarreal, Laura Elia
Medicina Universitaria. 2016;18(70):42--48
www.elsevier.es/rmuanl
REVIEW ARTICLE
Clinical  and genetic  aspects of Turner’s  syndrome
M. Ibarra-Ramírez ∗, L.E. Martínez-de-Villarreal
Department  of  Genetics  at  the  ‘‘Dr.  José  Eleuterio  González’’  University  Hospital  of  the  Autonomous  University  of  Nuevo  León,
Monterrey, Mexico
Received  27  November  2015;  accepted  26  January  2016
Available  online  17  May  2016
KEYWORDS
Turner  syndrome;
X  chromosome;
Short  stature
Abstract  Turner’s  syndrome,  or  monosomy  X,  is  defined  as  the  total  or  partial  loss  of  the
second sex  chromosome.  The  clinical  phenotype  is highly  variable  and  includes  short  stature,
gonadal dysgenesis,  pterygium  colli, cubitus  valgus  and  low  hairline.  The  variable  expressivity
of height  and  other  physical  features  may  be only partially  related  to  the  chromosomal  formula.
Currently, the  delay  in  the  diagnosis  of Turner’s  syndrome  remains  a  problem,  as  only  15--30%
of patients  are  diagnosed  during  their  first  year  of  life.  Understanding  its  complex  etiology
and learning  more  about  its  clinical  variability  and  complications  will allow  us  to  advance  the
therapeutic  and  management  approach  of  such  patients.  This  review  summarizes  the  clinical
characteristics  of,  and  diagnostic  tests  for,  Turner’s  syndrome  and  the advances  in the  study  of
its underlying  genetic  factors.
©  2016  Universidad  Auto´noma de Nuevo  Leo´n.  Published  by  Masson  Doyma  Me´xico  S.A. This  is
an open  access  article  under  the CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
Introduction
Turner’s  syndrome,  or  monosomy  X,  is  defined  as  the  total
or  partial  loss  of the second  sex  chromosome,  either  X  or
Y.1 Clinical  phenotype  is  highly  variable  and includes  short
stature,  gonadal  dysgenesis,  pterygium  coli, cubitus  valgus
and  low  hairline.2,3 It  was  first  described  by  Ullrich  in Ger-
many  in  1930.4 In  1938, Turner’s  described  a  group of  seven
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women,  ages  between  15  and  23, who  presented  a series  of
physical  alterations,  mainly  characterized  by  a short  size
and  gonadal  dysgenesis.5 In  1959,  Ford  et al.  recognized
the syndrome’s  chromosomic  base,  they  found  that patients
presented  45 chromosomes  with  a single  X chromosome.6
Turner’s  syndrome  occurs  in 1 every  2500--3000  live
births  and  it  is  the  only  full monosomy  which  is  compati-
ble  with  life.2--4 Advances  in the  study  of  underlying  genetic
advances  allows  for a  greater  understanding  of  associated
co-morbidities.  Since  just 30%  of  TS cases  are  diagnosed
early,  a  proper and  timely  management,  with  a  subsequent
improvement  in quality  of life,  is  not  accomplished  in  most
patients.  This  paper  reviews  the main  clinical  character-
istics,  diagnostic  tools  and  advances  in the  study  of  its
underlying  genetic  factors.
http://dx.doi.org/10.1016/j.rmu.2016.03.003
1665-5796/© 2016 Universidad Auto´noma de Nuevo Leo´n. Published by Masson Doyma Me´xico S.A. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Chart  1  Clinical  characteristics  of  patients  with  Turner
syndrome.
Clinical  charactertistics  Frequency  (%)
Low  height  99
Short neck  50
Cubitus valgus  70
Pterigium colli  25
Low hair  line  80
Edema of  the  hands  and  feet  80
Hyperconvex and/or  deep  nails  70
Characteristic  dermatoglyphs 35
Gonadal  dysgenesis 96
Cardiovascular  disorders 50
Kidney  malformations  40
Pigmented nevi  50
Eyelid ptosis  11
Hearing impairment  50
Hashimoto’s  thyroiditis  30
Carbohydrate  intolerance  40
Clinical characteristics
The  variable  expressivity  of  height  and  other  physical  fea-
tures  may  be  only partially  related  to  the chromosomal
formula,  even  when  most  recent  studies  do  not  show  a  clear
genotype-phenotype  correlation.  Sometimes  the  phenotype
may  be  practically  normal,  which  occurs  more  frequently  in
cases  due  to  partial  monosomy  or  mosaicism.2 The  frequency
of  structural  and  functional  malformations  are  described  in
Chart  1.
Clinical phenotype
Short  stature  is  the most constant  data,  it is  present  in  over
90%  of  cases,2,4 it  varies  depending  on  country  of  origin
and  it  is  usually  20--22  cm  under  the average  population.7
TS’s  spontaneous  growth  is  characterized  by  a  moderate
intrauterine  growth  delay,  slow  growth  from  childhood,  with
a  progressive  separation  from  the average  population’s  size,
absence  of  puberty  development  and  bone  maturation  delay.
A  characteristic  sign  is  a  relative  widening  of  the tho-
rax  ‘‘shield  chest’’,  sometimes  linked  to  pectum  excavatum.
Extremity  alterations  are  frequent,  cubitus  valgus  and short-
ened  metacarpal  IV  are  both  classic,  more  constant  signs.
Less  frequent,  however  more  suggesting  is  Madelung  wrist
deformity,  observed  from  5 to  6 years  of age  and  charac-
terized  by  a  lower  growth  of the radius  with  respect  to  the
ulna,  generating  a progressive  dorsal  deformity  of the  radial
ulnar  joint  or  the ‘‘Dinner  fork  sign’’.  Regarding  the  lower
limbs,  genu  varum  and  metatarsal  shortening  may  be found.
Some  anomalies  in facial  bone  development  contribute
to  the  configuration  of  the ‘‘sphynx’’  face.  These  include
microrethrognatia  and  an underdeveloped  superior  maxilla,
which  result  in an ogival  palate  and  dental  malocclusion.
Other  frequent  facial  features  include  palpebral  ptosis,  stra-
bismus,  oblique  palpebral  openings  from  top  to  bottom,  a
thin  upper  lip  with  downward  commissures  and  a  long  fil-
trum,  epicanthal  folds  and  ear implantation  with  posterior
Figure  1  Craniofacial  dysmorphias  in a  patient  with  TS. Down-
slanting eyelid  openings,  ptosis,  low-set  pinnae  and  a wide  and
short neck  can  be observed.
rotation  as a consequence  of  the abnormal  development
of  the bones  at  the  base  of  the cranium  (Fig.  1).  These
bone  anomalies  predispose  a  greater  risk  of  presenting  otitis
media.
One  of the  most  typical  findings  during the neonatal
period  is  lymphedema  in  the feet  and hands,  which  is  a
result  of  a  drainage  deficit  due  to  hypoplasia  of  the  lym-
phatic  vessels  and  is  usually  transitory,  yet  it leaves  as  a
sequelae  hypoplastic,  narrow  and  convex  nails.  Said  abnor-
mal  drainage  has  visible  and  persistent  consequences  in  the
neck,  where  pterigium  colli  or  webbed  neck,  secondary
to  nuchal  hygroma  during  fetal  life, as  well  as  skin  folds
and  a low hair  line  and  ear  implantation  are  attributed  to
hygrome  absorption.  Pigmentary  nevus  are frequent,  along
with  telangectasias  and keloid  scars.
Cardiovascular  features
Congenital  structural  heart  diseases  affect  approximately
40%  of  TS patients  and  are an  important  cause  of early
mortality.8 These  anomalies  include narrowing  of  the  aorta,
a  bicuspid  aortic  valve  and abnormal  pulmonary  venous
returns.  Aortic  dilatation  occurs  in  15--30%  of  girls  with  TS1
and  depending  on  the size,  carries  a significant  risk  of dis-
section.  Aortic  dissection  incidence  in TS is  estimated  at
0.6--1.4%  with  a median  age of  30--35  years  of  age.9
Adult  patients  with  TS frequently  show  electrocar-
diographic  abnormalities,  including  axis  deviation  to the
right,  T-wave  abnormalities,  accelerated  AV  conduction  and
prolongation  of  the  QT-interval,  often  independent  from
structural  defects.10 Essential  hypertension  affects  up  to  a
25%  of adolescents  and  50%  of adult  patients.
Endocrine  and reproductive features
A  greater  susceptibility  to  endocrine  and autoimmune
diseases  is  well-documented  in these patients.11 Thyroid
disease  has been  reported  in up  to  30%,  with  hypothyroidism
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secondary  to  Hashimoto  thyroiditis  being  the most  prevalent
affection.  Moreover,  a pro-atherogenic  lipid  profile  and
glucose  intolerance  with  progression  to  type II diabetes
mellitus  are  also  frequent  (2--4  times  higher  risk  than the
general  population),  abnormalities  which,  with  a  probable
intrinsic  vasculopathy,  explains  the high  mortality  rates
by  coronary  and  cerebrovascular  diseases.4 Approximately
85%  of  patients  with  a  chromosomal  formula  45,  X have
a  total  loss  of  germinal  cells at birth,  10--15%  of  these
have  enough  germinal  cells  to  develop  a  pubertal  response
and  5% of  them  have  enough  germinal  cells  to  allow  for
pubertal  development  and  spontaneous  menstrual  cycles,
with  a  premature  menopause  at around  30  years  of  age.12--14
Natural  pregnancy  is  produced  in approximately  1--2%  of  all
women  with  TS, but  with  a  greater  risk  of  loss.14
Other  associated features
Congenital  malformations  of  the  urinary  system  occur  in
30--40%  of patients.15 The  most  frequent  malformations  are
collecting  system  alterations  (20%),  horseshoe  kidney  (10%)
and  positional  abnormalities  (5%). Strabismus  and  farsight-
edness  occur  in 25--35% of  these  girls,  increasing  the  risk
of  amblyopia.  Green-red  color  blindness  occurs  in ∼8%,
a  higher  prevalence  than  that  observed  in women  with-
out  TS  due  to color  blindness  deficiency  has  an X linked
inheritance.16 Likewise,  other  monogenic  disorders  linked
to  chromosome  X,  like  Duchenne  muscular  dystrophy  or
hemophilia  (both  A  and  B),  can  affect  patients  with  TS.
Genetic aspects
This  aneuploidy  originates  for the most part  from  a non-
disjunction  phenomenon  which  affects  the paternal  genome
in  60--80%  of  cases.3 Around  50--60%  of patients  present  a
full  X  monosomy,  which  is  defined  as  the  absence  of  the
second  sexual  chromosome  and  expressed  with  formula  45,
X.  Between  20  and  40%  represent  mosaics  of  two  or  more  cell
lines  derived  from  the same  zygote  (Chart  2).  Mosaicism  may
be  limited  to  tissues  that  do not include  peripheral  blood,
making  its  diagnosis  difficult  unless  studying  the affected
tissue.2
Structural  alterations  of the X chromosome  can  be found
in  20%  of  cases  (Fig.  2), the isochromosome  of  the long  arm
being  most  frequent.  Moreover,  there  can  also  be rings  and  X
Chart  2  Distribution  of  chromosomal  alterations  present
in Turner’s  syndrome.
Chromosomal  formulas  Percentage
45,X  50--60
mos 45,X/46,XX  20
mos 45,X/47,XXX/46,XX  3--5
mos 45,X/46,XY
45,X/46,X,i(Xq) 10--23
45,X/46,X,+ring
45,X/46,X,+mar
46,X,  del(Xq)
46,X,del(Xp)
chromosome  deletion  of both  the short  and  the long  arms;  in
3--5%  we  are able  to  find  cell lines  with  a  46,  XY  complement
or  Y  chromosome  derived  chromosomic  markers.
The  X chromosome  contains  155 million  pairs  of  bases
(pb)  and  over 1000  genes16 while  the  Y  chromosome  has  a
length  of 60  million  pb  and  contains  over  200  genes,  from
which  only 48  are codifiers.17 Inactivation  of  the  X chromo-
some  in women  allows  for an  equilibrium  in gene doses  with
respect  to  men; however,  the  so-called  pseudoautosomic
regions  (PAR1  and PAR2)  escape  X chromosome  inactivation
and  their  genes  are  counterparts  to  those  within  PAR1  and
PAR2  of  the Y  chromosome.  Hence,  a  proper  expression  and
function  of these  genes  requires  both  alleles. Additionally,
only  in said regions is  there  a  meiotic  recombination  among
X  and  Y  chromosomes.
The PAR1  region  covers  2.6  Mb  of  the short  arm  of  X  and
Y  human  chromosomes.18,19 It  contains  at least  24  genes,  all
of  which  escape  X  inactivation.6 The  PAR2  region  is in the
distal  end  of  the  long  arm, and  is  much  smaller  since  it only
covers  320  kb7.  It presents  a lower  recombination  frequency
and  is  composed  of  pseudogenes,  for  the  most  part.  Four
genes  have  been  identified  in  this  region  (HSPRY3,  VAMP7,
IL9R  and CXYorf1) located  in  a telomeric  center  direction.
The  Turner’s  syndrome  phenotype  can  be  explained
by  a  haploinsufficiency  of  the genes  which  are normally
expressed  in both  sexual  chromosomes  and  which  escape
X  inactivation.  The  SHOX  gene  (short-stature  homebox)
located  in  Xp22.23  (PAR1)  belongs  to the  homebox  gene
family,  which  is  a  transcriptional  regulator  and  key  con-
troller  of  multiple  processes  during  embryonic  development.
Location  of the SHOX  expression  during embryogenesis  is
correlated  to  many  phenotypic  features  of  Turner’s  syn-
drome,  since  it intervenes  in  the development  of the elbow
and  knee,  its  haploinsufficiency  is associated  with  skele-
tal  alterations  such  as  cubitus  valgum,  genu  valgum  and
Madelung  deformity.  Its  expression  in the first and second
pharyngeal  arches  takes  part  in the formation  of  the upper
and  lower  maxillary,  ears  and external  hearing  meatus,20
hence  its  link to  a  narrow  palate  and  retrognathia.  Short
size  is  explained  by  the SHOX  haploinsufficiency,  which  acts
as  a transcription  factor  over  the B-type  natriuretic  pep-
tide  (BNP),  expressed  mainly  in  cardiac  tissue  and better
known  by  its  vasodilator  properties.  However,  BNP  is  also
expressed  in other  tissues,  including  cartilage,  where it is
necessary  for normal  chondrogenesis.21 Other  genes  located
in the short  arm  of  the  X  chromosome  may  contribute  to  the
variability  observed  in  the delay  in growth.  As  mentioned
above,  BPN’s predominant  expression  in cardiac  tissue  and
its  transcriptional  control  by  the SHOX  gene  may  explain
cardiac  alterations  in  these patients.
Although  there  are no  genetic  findings  which  explain  vis-
ceral  and  soft  tissue affectation,  some phenotypical  data
such  as  lymphedema,  pterigium  colli  and  cardiac  abnormali-
ties  have been  linked  with  lymphatic  hypoplasia  attributable
to  other  genes  which  escape  X  chromosome  inactivation
and  are  located  in  the Xp11.39  region.  Immunohistochemi-
cal  studies  conducted  in fetuses  with  TS  showed  a decrease
in  the expression  of  endothelial  and  vascular  growth  factor
(FLT4,  PTN63, LYVE1, Prox1)  receptors,  a decrease  that may
be  linked  to  abnormal  lymphatic  genesis.22,23
Since  structural  alterations  of  the heart  and  vascular
system  are  much  more  common  in girls  with  cystic  hygroma
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Figure  2  Examples  of  chromosome  X  structural  alterations.  (A)  Isochromosome  of  the  long  arm  of  X.  (B)  Chromosomal  mark  and
a ring.  (C)  Deletion  of  the  short  arm  of  the  X  chromosome.  (D)  Deletion  of  the  long  arm  of  X  chromosome.
or lymphedema,  it has been  suggested  that  abnormal  lymph
nodes  are  involved  in the development  of these  heart
diseases.  Moreover,  it has been  speculated  that  aortic
coarctation  is  the result  of  abnormal  lymphatic  flow,  which
is  characteristic  of  TS.  On  the other  hand,  there  is  the
hypothesis  that  myocardial  hypoplasia  is  a primary  defect
caused  by  lymphedema;  since  over  90%  of  fetuses  with
TS  course  with hydrops,  the  heart  weighs  under  the  2.5th
percentile  (in  relation  to the weight  of  other  organs  and
gestational  age)  while  an altered  heart  weight  was  less
common  in  those  fetuses with  hydrops  of  other  etiologies.24
Zinn  et  al.  suggested  a hypothesis  where  a still  undis-
covered  gene  located  in  PAR1  causes  all  the neurocognitive
problems  of TS. They  identified  a region  of 8.3Mb  Xp22.33
whose  haploinsufficiency  is enough  for  the expression  of
TS  neurocognitive  phenotypes.25,26 The  VSPA  (Xp22.33)  gene
is  clearly  related  to  visuospatial  alterations  of  patients
with  TS.27 The  NLGN4X  gene,  proximal  to  PAR1  but  within
the  8.3  Mb  critical  region,  is  another  candidate  to  explain
said  neurocognitive  deficit.  Nevertheless,  it is  probable  for
neurocognitive  manifestations  characteristic  of TS  to  be
of  multifactorial  origin,  a result  of interactions  between
genetic  and  hormonal  abnormalities  and other  unknown
determinants.28
Two  regions  of  the  X chromosome  contain  crucial  genes
for  the  development  and  function  of  the ovary:  The  pre-
mature  ovarian  failure  region  1 known  as  POF1,  located  in
Xq26-28,  and the  premature  ovarian  failure  region  II  (POF2),
in  Xq13.3-2.229, include  known  genes  as  well  as  candidate
genes. In  POF1, there  are candidate  genes  HS6ST2,  TDPf3,
and  GPC3,  as  well  as  the  FMR1  gene,  which  is clearly  linked
to  premature  ovarian  failure.30 There  are  genes  linked  to
ovarian  failure  in POF2,  such  as  RPS4X  (a gene  which  cod-
ifies  an isoform  of the  S4 ribosomal  protein)  and DIAPH2
(Drosophila  homologue  diaphone).
Other  genes  outside  of POF regions,  such  as  DFFRX
or  USP9X  (Drosophila  fat  facets  related  to  X) in  Xp11.4,
ZFX  (zinc  finger)  in Xp22.11,  UBA1  (ubiquitin-like  enzyme
activator-modifier)  in  Xp11.23  and DBX  (Dead/H  BOX  3,
X-linked)  also  escape  X chromosome  inactivation  and  are
related  to  the development  and maintenance  of  ovarian
function.14
Women  with  TS  have a  greater  prevalence  of  autoimmune
diseases  such as  Hashimoto  thyroiditis,  celiac  disease  and
ulcerative  colitis.  As  a  matter  of fact,  Hashimoto  thyroidi-
tis  occurs  in  37%  of  patients  with  TS.31 There  are  at  least
ten  genes  located  in the  X  chromosome  that  have  possible
immune  regulatory  functions.  One  of  them  is  FOXP3, which
codes  a transcription  factor  essential  for natural  regulatory
T-cell  function  (a  subgroup  of  CD4  lymphocytes),  which  sup-
presses  peripheral  auto-reactive  T-cells.  Since mutations  of
this  gene  create  a syndrome  called  immunodysregulation,
polyendocrinopathy  and  enteropathy  linked  to  the  X  chro-
mosome  and  its  haploinsufficiency  would explain  part  of  the
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Figure  3 Diagnostic  algorithm  for  Turner  syndrome.  *Chronic  villus.
increase  in the prevalence  of  these  diseases  in TS patients.
It  is important  to  mention  that  the risk  of  autoimmune  dis-
eases,  especially  thyroid  disease,  is particularly  greater  in
patents  who  present  an isochromosome  formation  in the
long  arm  of  the  X chromosome  (Xq).32
Diagnosis
Diagnosis  is  suspected  in  the  function  of  clinical  and hor-
monal  findings.  However,  it requires  a confirmation,  by  a
conventional  Karyotype  (GTG  bands)  or  other  cytogenetic
analysis,  of the  subjacent  aneuploidy.  The  cytogenetic  study
ought  to include  a  recount  of  at  least 30  metaphases  in order
to  be  able  to  exclude  mosaics  in  10%  with  a confidence  inter-
val  of  95%.33 In those  cases  where there  is  a great  suspicion
of  TS and  the  peripheral  blood  caryotype  is  normal,  study-
ing  a  second  tissue  is  indicated,  usually  in fibroblasts,  thus
ruling  out  a  mosaicism.
Approximately  3--6%  of  women  with  TS have  a 45X/46,
XY  mosaic  and  with  it the  risk  of presenting  gonadoblastoma
throughout  their  lives  is  between  7% and  30%.2 Hence, ruling
out  the  existence  of  sequences  of the  SRY  gene by  using
molecular  cytogenetic  techniques  such as  fluorescence  by
‘‘in  situ’’  hybridization  (FISH)  or  polymerase  chain  reaction
techniques  (PCR)  is  important  (Fig.  3).34,35
Prenatal diagnosis
There  are  certain ultrasonographic  findings  which  suggest
TS.  An  increase  in nuchal  translucency  is  seen  in  TS, but  it
can  also  be  observed  in other  chromosome  disorders.  The
presence  of  septated  cystic  hygroma  makes  a TS  diagno-
sis  more  likely.36 Other  suggestive  echo-graphic  findings  are
aorta  coarctation  and/or  structural  heart  defects,  brachy-
cephaly,  malformations,  polyhydramnios,  oligohydramnios
and  growth  delay.  Abnormal  results  in  triple  or  quadru-
ple  marker  analysis  in  maternal  serum  (fetus-protein,  beta
chorionic  gonadotropin,  unconjugated  estriol  and  inhibit  A)
may  also suggest  a TS  diagnosis  and justify  invasive  studies
such  as  chorionic  villus  biopsy  or  amniocentesis  in  order  to
perform  a  Karyotype  or  FISH2 (Fig.  3).
Neonatal screening
Sub-diagnosis  and  delays  in TS diagnosis  remain  a
problem.37,38 Even  in  countries  where  prenatal  diagnosis  is
common,  reports  show  that  between  15--30%  of  patients  are
not  diagnosed  until  after  12  years  of age.  It  is  important  to
stress  the  fact  that  early  detection  allows  for  proper  iden-
tification  and  timely  management  of related  complications.
There  are  molecular  techniques  which  may  be applied  to
neonatal  detection  of aneuploidies  of  sexual  chromosomes,
thus  defeating  diagnostic  delay.23,39--41 However,  these  have
not  been  validated  in newborn  population.
Treatment
Treatment  for these  patients  ought  to be multidisci-
plinary,  with  the participation  of  pediatricians,  endocri-
nologists,  ophthalmologists,  otorhinolaryngologists,  car-
diologists,  geneticists,  psychologists,  gynecologists  and
reproduction  biologists.
Today,  growth  hormone  and  estrogen  replacement  ther-
apy results  are fundamental  for  these  patients.42 Moreover,
there  is  reliable  information  stating  that  the combination  of
very  low estrogen  doses  with  growth  hormones  during  child-
hood  can  improve  the  final  size and  provide  other  potential
benefits  linked  to  early  estrogen  replacement.43
Assisted  reproduction  allows  for  patients  to  get  pregnant,
if they  chose to  do  so; furthermore,  early  TS detection
allows  for oocyte cryopreservation  consideration  and later
a  pregnancy  in adult  life.
Follow-up  of  these patients  throughout  their  lives is
important,  with  the purpose  of  a  timely  detection  of  concur-
rent  diseases  and  prevention  of  possible  complications.  In
Chart  3 there  is  a  guide  of  periodic  evaluations  and recom-
mended  complementary  studies.
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Chart  3  Multi-disciplinary  management  in  patients  with
Turner’s syndrome.
All  patients
Cardiovascular  evaluation
Renal  ultrasound
Hearing  evaluation  by  a  specialist
Screening  for  scoliosis/kyphosis
Neuropsychological  evaluation;  referral  to  support  groups
Evaluation  of  growth  and  pubertal  development
Age 0--4  years
Evaluation  for  hip  dislocation
Thyroid  function  tests  (T4, TSH)
Ophthalmological  examination  (if  age  ≥1  year)
Age  4--10  years
Thyroid  function  (T4,  TSH)  and  Celiac  Disease  (TTG  Ab)
tests
Education/psychosocial  assessments
Dental  evaluation  (if  age  >7  years)
Age >10  years
Thyroid  function  (T4,  TSH)  and  Celiac  Disease  (TTG  Ab)
tests
Education/psychosocial  assessments
Dental  evaluation
Fasting  glucose  or  glucose  tolerance  curve
Assessment  of  ovarian  function/estrogen  replacement
Liver function  tests,  lipid  profile,  creatinine,  BUN,  urea
and complete  blood  count
Bone  densitometry  (if  age  >18 years)
Conclusion
Turner’s  syndrome  is  a chromosomic  disorder,  a  result  of  the
partial  or  total  absence  of the second  sexual  chromosome.
A  relatively  frequent  alteration  (1:2500  newborn  girls),  it
presents  a  phenotypical  variability  which  may  cause  a sub-
diagnosis  of  its  cases.
It  is  important  to  know  the  clinical  and  genetic  aspects
which  will  lead  to  a timely  detection  of  cases,  and thus
a  proper  management  of  associated  co-morbidities  to  this
genetic  condition.
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